182 results
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
discussions of strategy or other intentions, particularly as they relate to the development and funding of our product candidates.
We caution … and opportunity for and clinical utility of our product candidates, if approved for commercial use;
Our manufacturing capabilities and strategy
424B5
OGEN
Oragenics Inc
27 Feb 24
Prospectus supplement for primary offering
5:04pm
, or other variations of those terms or comparable language, including discussions of strategy or other intentions, particularly as they relate … for commercial use;
Our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes
8-K
OGEN
Oragenics Inc
16 Jan 24
Other Events
9:10am
on the viability of our business strategy with regard to those assets, which is unproven and may be unfeasible.
Our revenue and income potential with regard … to the Neurology Assets, in particular the concussion asset, are unproven, and we continue to develop our strategy for such assets. Our anticipated
424B5
OGEN
Oragenics Inc
16 Jan 24
Prospectus supplement for primary offering
9:04am
variations of those terms or comparable language, including discussions of strategy or other intentions, particularly as they relate to the development … ;
Our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes, and those
8-K
ggkou4tbsj7tjou87
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am